Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers

Arquivos de Neuro-Psiquiatria

Enedina Maria Lobato De Oliveira¹  Renata Faria Simm¹  Gorana Dasic¹  Marília Mamprim De Morais¹  Samira Luiza Dos Apostolos Perreira¹  Dagoberto Callegaro¹ 

关键词: natalizumab;    multiple sclerosis;    disability progression;    relapse rate;    natalizumabe;    esclerose múltipla;    progressão da incapacidade;    taxa de surto;   

DOI  :  10.1590/0004-282X20150098

来源: SciELO

【 摘 要 】

Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ≤ 3.0 vs patients with EDSS > 3.Results Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy.Conclusion Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License